Ashley’s BENLYSTA treatment

Hypothetical patient profile. May not be representative of all patients.

video transcript

ASHLEY: I started therapy for my lupus nephritis right away. My new treatment plan included BENLYSTA, which is available for patients like me with lupus nephritis.

[ON-SCREEN TEXT: Ashley’s initial treatment plan*: Cyclophosphamide; High-dose steroids; Benlysta IV 10 mg/kg: Every 2 weeks for the first 3 infusions; Every 4 weeks thereafter]

[ON-SCREEN TEXT: * Hypothetical patient profile. May not be representative of all BENLYSTA patients.]

ASHLEY: It’s been a few months, and so far this treatment plan is working for me. My labs have improved, and we think it might be time to start reducing my steroid dose. My BENLYSTA treatment will remain the same though.

[ON-SCREEN TEXT: Results may vary.]

ASHLEY: Thankfully I have a lot of support, and that’s helping me maintain a positive outlook. I’m hopeful this treatment plan can help my lupus and kidney disease from getting worse.

[ON-SCREEN TEXT: Results may vary.]

VOICEOVER: IMPORTANT PRODUCT INFORMATION: For patients on standard therapy: Aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis. Not for use in severe active central nervous system lupus. Reported: serious & sometimes fatal infections; progressive multifocal leukoencephalopathy; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

[ON-SCREEN TEXT: IMPORTANT PRODUCT INFORMATION
For patients on standard therapy: Aged 5+ and older with active SLE or active lupus nephritis. Not for use in severe active CNS lupus. Reported: serious & sometimes fatal infections; PML; acute hypersensitivity reactions, including anaphylaxis & death, and infusion-related reactions; and, depression & suicidality. Avoid live vaccines. Common adverse reactions: nausea, diarrhea, pyrexia, nasopharyngitis, bronchitis, insomnia, pain in extremity, depression, migraine, pharyngitis, & injection site reactions.

Please see the full Important Safety Information for BENLYSTA on this page. Please click the link to view full Prescribing Information, including Medication Guide, for BENLYSTA.]

[ON-SCREEN TEXT: IMPORTANT PRODUCT INFORMATION

[ON-SCREEN TEXT:
Benlysta
(belimumab)
Intravenous Use 120 mg/Vial
Subcutaneous Use 200 mg/mL

Trademarks are owned or licensed to the GSK group of companies. ©2024 GSK or licensor. BELVID230035 January 2024. Produced in USA.

[ON-SCREEN TEXT: GSK]

[ON-SCREEN TEXT: Ahead Together]

You may also like

See Ashley’s diagnosis story

Hypothetical patient profile. May not be representative of all patients.

Icon: Computer

Join us for a live webinar

Learn more